SUBSCRIBE
SUBSCRIBE

Huntington’s disease

Pictured: FDA signage at its office in Washington, DC
FDA
Neurocrine Wins FDA Approval for ‘Sprinkle’ Formulation of Ingrezza for Huntington’s Disease Chorea
Neurocrine Biosciences on Tuesday won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
May 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A scientist with pill bottles in front of FDA headquarters/Taylor Tieden for BioSpace
Policy
FDA Action Alert: ImmunityBio, Aquestive, XOMA and More
The FDA will close out April with five target action dates around indications that include pediatric seizures and a neurological cancer in children.
April 18, 2024
 · 
6 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington’s Disease Treatment
October 21, 2025
 · 
2 min read
Press Releases
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington’s Disease Chorea
October 7, 2025
 · 
13 min read
Press Releases
NeuraLight and CHDI Foundation Collaborate to Develop Precision Eye Movement Biomarkers for Huntington’s Disease
September 10, 2025
 · 
2 min read
Press Releases
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington’s Disease Chorea
June 27, 2025
 · 
15 min read
Press Releases
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington’s Disease
June 17, 2025
 · 
4 min read
Press Releases
NUZ-001 Shows Promise in Zebrafish Model of Huntington’s Disease
June 16, 2025
 · 
6 min read
Press Releases
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
June 2, 2025
 · 
11 min read
Press Releases
Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research
May 28, 2025
 · 
4 min read
Press Releases
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
April 17, 2025
 · 
6 min read
Press Releases
ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease
February 24, 2025
 · 
5 min read
Press Releases
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
February 24, 2025
 · 
3 min read
Press Releases
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
November 20, 2024
 · 
4 min read
Press Releases
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington’s Disease Through Week 104 Irrespective of Antipsychotic Use
September 30, 2024
 · 
14 min read
Press Releases
Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington’s Disease
September 13, 2024
 · 
5 min read
Press Releases
Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington’s Disease Network and Enroll-HD 2024
September 11, 2024
 · 
4 min read
Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
July 10, 2024
 · 
5 min read